Amicus Therapeutics (FOLD) has risen sharply, recording gains of 3.87% in the past 4 weeks. However, the stock has corrected -0.57% in the past 1 week, providing a good buying opportunity on dips. Amicus Therapeutics (FOLD) : Traders are bullish on Amicus Therapeutics (FOLD) as it has outperformed the S&P 500 by a wide margin of 4.09% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.09%, relative to the S&P 500.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.62% and the fifty day Moving Average is 11.18%. Amicus Therapeutics, Inc. has dropped 1.13% during the last three month period . Year-to-Date the stock performance stands at -28.04%.
Amicus Therapeutics (FOLD) : 6 Wall Street analysts covering Amicus Therapeutics (FOLD) believe that the average level the stock could reach for the short term is $13.33. The maximum price target given is $19 and the minimum target for short term is around $9, hence the standard deviation is calculated at $3.72.
Amicus Therapeutics (NASDAQ:FOLD): The stock was completely flat for the day, closing at $6.98 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $7.05, the stock touched an intraday high of $7.20 and a low of $6.63. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $6.98. The total trading volume on Friday was 2,598,818.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.